| Trial registration number
|
IRCT20201122049463N1 |
Full text link
Last imported at : Jan. 19, 2021, 1 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
http://en.irct.ir/trial/52495
|
First author
Last imported at : Jan. 19, 2021, 1 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Dr Shaghayegh Haghjooy
|
Contact
Last imported at : Jan. 19, 2021, 1 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
sh_haghjoo@med.mui.ac.ir
|
Registration date
Last imported at : Jan. 19, 2021, 1 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
2021-01-18
|
Recruitment status
Last imported at : Feb. 10, 2021, 1 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Completed
|
Study design
Last imported at : Jan. 19, 2021, 1 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
RCT
|
Allocation
Last imported at : Jan. 19, 2021, 1 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Randomized
|
Design
Last imported at : Jan. 19, 2021, 1 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Parallel
|
Masking
Last imported at : Jan. 19, 2021, 1 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Open label
|
Center
Last imported at : Jan. 19, 2021, 1 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
single-center
|
Study aim
Last imported at : Jan. 19, 2021, 1 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Treatment
|
Inclusion criteria
Last imported at : Jan. 19, 2021, 1 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Positive nasopharyngeal or oropharyngeal PCR test
No sign of underlying disease such as auto immunity disorders
No sign of diabetes
No sign of lung cancer
SPO2 ( 85%-90%) , with out using external oxygen sources.
|
Exclusion criteria
Last imported at : Jan. 19, 2021, 1 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Patient's age > 75
SAO2 decrease 48 hours after local hyperthermia
|
Number of arms
Last imported at : Jan. 19, 2021, 1 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
2
|
Funding
Last imported at : Jan. 19, 2021, 1 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Esfahan University of Medical Sciences
|
Inclusion age min
Last imported at : Jan. 19, 2021, 1 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
17
|
Inclusion age max
Last imported at : Jan. 19, 2021, 1 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
75
|
Countries
Last imported at : Jan. 19, 2021, 1 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Iran
|
Type of patients
Last imported at : Jan. 19, 2021, 1 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Severe disease at enrollment
|
Severity scale
Last imported at : Jan. 19, 2021, 1 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
6: Severe disease at enrollment
|
Total sample size
Last imported at : Jan. 19, 2021, 1 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
60
|
primary outcome
Last imported at : Jan. 19, 2021, 1 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Blood oxygen saturation
|
Notes
Last imported at : Jan. 19, 2021, 1 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
|
Phase
Last imported at : Jan. 19, 2021, 1 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Phase 2/Phase 3
|
Arms
Last imported at : Jan. 19, 2021, 1 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
[{"arm_notes": "", "treatment_id": 272, "treatment_name": "Chest wall hyperthermia", "treatment_type": "Medical device", "pharmacological_treatment": "Non pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]
|